<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738852</url>
  </required_header>
  <id_info>
    <org_study_id>2000023189</org_study_id>
    <nct_id>NCT03738852</nct_id>
  </id_info>
  <brief_title>Mechanisms for Restoration of Hypoglycemia Awareness</brief_title>
  <official_title>Mechanisms for Restoration of Hypoglycemia Awareness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if using the hypoglycemic clamp and functional magnetic resonance imaging (fMRI)&#xD;
      scanning in hypoglycemia unaware and aware T1DM patients and healthy controls have showed&#xD;
      distinct differences in patterns of brain responses. In particular, T1DM patients who are&#xD;
      aware of hypoglycemia (T1DM-Aware) have greater activity in sensory integration brain regions&#xD;
      (e.g. parietal lobe and caudate nucleus) in response to hypoglycemia, whereas hypoglycemia&#xD;
      unaware T1DM patients (T1DM-Unaware) show no detectable changes in brain reward regions&#xD;
      during hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the following: 1) if these differences are driven purely by recurrent hypoglycemia&#xD;
      or by other closely linked factors (e.g. glycemic variability); 2) the molecular and&#xD;
      metabolic mechanisms by which unawareness leads to the suppression of central nervous system&#xD;
      (CNS) activity in the context of hypoglycemia; and 3) whether hypoglycemia avoidance using&#xD;
      continuous glucose monitor restores central nervous system (CNS) activation and metabolism&#xD;
      toward normal levels and offers a therapeutic approach to more effectively combat&#xD;
      neurocognitive dysfunction associated with intensive treatment of T1DM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain glucose levels</measure>
    <time_frame>3 months</time_frame>
    <description>Brain glucose will be lower and brain activation higher in those receiving continuous glucose monitor Rx.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous Glucose Monitor for 3 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 1: Impact of hypoglycemia on brain connectivity Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls, T1 aware, and T1 unawares</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls, T1 aware, and T1 unawares</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitor (CGM)</intervention_name>
    <description>Continuous Glucose Monitor (CGM)</description>
    <arm_group_label>Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months</arm_group_label>
    <other_name>Dexcom G6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>standard insulin regimen</description>
    <arm_group_label>Aim 1: Impact of hypoglycemia on brain connectivity Type 1</arm_group_label>
    <arm_group_label>Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1</arm_group_label>
    <arm_group_label>Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages &gt; 18 years&#xD;
&#xD;
          -  Healthy, non-diabetic control or T1DM&#xD;
&#xD;
          -  BMI &gt; 18.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
          -  Hct &lt; 35% for females, &lt; 39% for males&#xD;
&#xD;
          -  ALT &gt; 2.5 X ULN&#xD;
&#xD;
          -  untreated thyroid disease&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  neurologic disorders&#xD;
&#xD;
          -  untreated depression or change in antidepressant regimen in last 3 months&#xD;
&#xD;
          -  use of any anxiolytic medications (benzodiazepine) or antipsychotic medications&#xD;
&#xD;
          -  greater than 5% change in weight in last 3 months&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  current or recent steroid use in last 3 months&#xD;
&#xD;
          -  illicit drug use&#xD;
&#xD;
          -  significant complications related to diabetes (peripheral neuropathy, proliferative&#xD;
             retinopathy)&#xD;
&#xD;
          -  inability to enter MRI (per standard MRI safety guidelines)&#xD;
&#xD;
          -  for women: pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Hwang, Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janice Hwang, MD</last_name>
    <phone>203-785-6222</phone>
    <email>janice.hwang@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation (YCCI) Church Street Research Unit (CSRU)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

